Zoetis Inc. (NYSE: ZTS) showcases remarkable growth in Q3 2024 with a revenue of $2.4 billion. The company’s dominance in the animal health sector is backed by innovative products and strategic advancements across companion and livestock segments.
Edwards Lifesciences’ Q3 2024 results highlight a strong growth trajectory with a 9% increase in sales, driven by TAVR and TMTT segments, positioning the company for future success.
